Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice
AuthorsBoguszewski, M. C. S.
Cardoso-Demartini, A. A.
Boguszewski, C. L.
Higham, Claire E
Yuen, K. C. J.
AffiliationDepartamento de Pediatria, Universidade Federal do Paraná, Avenida Agostinho Leão Junior, 285 - Alto da Glória, Curitiba, PR, 80030-110, Brazil.
MetadataShow full item record
AbstractIndividuals surviving cancer and brain tumors may experience growth hormone (GH) deficiency as a result of tumor growth, surgical resection and/or radiotherapy involving the hypothalamic-pituitary region. Given the pro-mitogenic and anti-apoptotic properties of GH and insulin-like growth factor-I, the safety of GH replacement in this population has raised hypothetical safety concerns that have been debated for decades. Data from multicenter studies with extended follow-up have generally not found significant associations between GH replacement and cancer recurrence or mortality from cancer among childhood cancer survivors. Potential associations with secondary neoplasms, especially solid tumors, have been reported, although this risk appears to decline with longer follow-up. Data from survivors of pediatric or adult cancers who are treated with GH during adulthood are scarce, and the risk versus benefit profile of GH replacement of this population remains unclear. Studies pertaining to the safety of GH replacement in individuals treated for nonmalignant brain tumors, including craniopharyngioma and non-functioning pituitary adenoma, have generally been reassuring with regards to the risk of tumor recurrence. The present review offers a summary of the most current medical literature regarding GH treatment of patients who have survived cancer and brain tumors, with the emphasis on areas where active research is required and where consensus on clinical practice is lacking.
CitationBoguszewski MCS, Cardoso-Demartini AA, Boguszewski CL, Chemaitilly W, Higham CE, Johannsson G, et al. Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors—a review of research and clinical practice. Pituitary. 2021 Jul 25.
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
- Authors: Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR
- Issue date: 2019 Nov
- Cancer risk following growth hormone use in childhood: implications for current practice.
- Authors: Ogilvy-Stuart AL, Gleeson H
- Issue date: 2004
- Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
- Authors: van Varsseveld NC, van Bunderen CC, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML
- Issue date: 2016 Aug
- Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement.
- Authors: Darzy KH, Shalet SM
- Issue date: 2006 Jul
- Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.
- Authors: Gasco V, Caputo M, Cambria V, Beccuti G, Caprino MP, Ghigo E, Maccario M, Grottoli S
- Issue date: 2019 Feb